open-label extension: phase 3 opera i and ii trials in relapsing ms
Published 4 years ago • 141 plays • Length 2:54Download video MP4
Download video MP3
Similar videos
-
5:07
open-label extension: btki in relapsing ms over 108 weeks
-
2:15
actrims 2020 news network: opera i/ii trials on relapsing ms
-
4:23
opera i & ii trials show promise for two forms of multiple sclerosis
-
5:20
results of ocrelizumab in treatment-naïve patients with early relapsing ms
-
6:01
ocrelizumab for relapsing ms
-
5:58
clinical trials of relapsing and primary progressive multiple sclerosis
-
1:00:54
re-examining s1pr modulation from all angles in relapsing multiple sclerosis
-
5:54
ensemble study results, ocrelizumab as promising early treatment for ms
-
5:14
role of ozanimod in multiple sclerosis
-
5:48
multiple sclerosis clinical research 101: ms clinical trials
-
![ocrevus in primary progressive multiple sclerosis 6.5-year data [orotorio extension study]](https://i.ytimg.com/vi/YN0u0dYFYgQ/mqdefault.jpg)
14:19
ocrevus in primary progressive multiple sclerosis 6.5-year data [orotorio extension study]
-
4:32
long-term results of ocrelizumab in treatment-naive patients with early relapsing ms
-
3:57
xavier montalban, ean 2020 – long-term phase ii outcomes of first oral btk inhibitor in ms
-
2:36
chimes: ocrelizumab in black/african american and hispanic/latino individuals with relapsing ms
-
0:30
ocrevus 3 times a year?!
-
8:24
role of siponimod in multiple sclerosis
-
39:42
dr martin duddy - a review of current clinical trials in ms
-
5:44
are ms clinical trials safe?